June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Patient Adherence and Persistence with Topical Ocular Hypotensive Therapy: a Claims-Based Comparison of Bimatoprost 0.01% and Travoprost with sofZia
Author Affiliations & Notes
  • Joanna Campbell
    GHOSR, Allergan, Irvine, CA
  • Gail Schwartz
    Greater Baltimore Medical Center, Baltimore, MD
    Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Britni LaBounty
    Principled Strategies, Inc., Encinitas, CA
  • Jonathan Kowalski
    GHOSR, Allergan, Irvine, CA
  • Vaishali Patel
    GHOSR, Allergan, Irvine, CA
  • Footnotes
    Commercial Relationships Joanna Campbell, Allergan Inc (E); Gail Schwartz, Allergan (C), Tissue Banks International (R), Allergan (R); Britni LaBounty, Allergan (C); Jonathan Kowalski, Allergan Inc (E); Vaishali Patel, Allergan, Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4403. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joanna Campbell, Gail Schwartz, Britni LaBounty, Jonathan Kowalski, Vaishali Patel; Patient Adherence and Persistence with Topical Ocular Hypotensive Therapy: a Claims-Based Comparison of Bimatoprost 0.01% and Travoprost with sofZia. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4403. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare patients’ adherence and persistence with bimatoprost 0.01% and travoprost 0.004% with sofZia ocular hypotensive therapy in real-world settings.

Methods: Pharmaceutical claims from a major, longitudinal database of prescription and medical claims for >115 million patients were analyzed. Patients with an initial prescription for bimatoprost 0.01% or travoprost 0.004% with sofZia between April and June 2011, and with no medication claim for a topical prostaglandin analog or prostamide during the previous 18 months, were identified. Persistence over 12 months was assessed using Kaplan-Meier survival analyses, assuming a 30-day grace period for prescription refill. Adherence was measured as the mean and median proportion of days covered (PDC) with drug supply (calculated using the number of drops/bottle and dose), and the proportions of patients with PDC ≤0.2 and >0.8.

Results: In total, 10,470 patients were included in the adherence analysis (4,131 on bimatoprost 0.01%; 6,339 on travoprost 0.004% with sofZia) and 12,985 patients in the persistence analysis (5,099 on bimatoprost 0.01%; 7,886 on travoprost with sofZia). Overall adherence was greater with bimatoprost 0.01% than with travoprost 0.004% with sofZia (mean PDC 54.0% vs 48.6%, p<0.001; median PDC 51.2% vs 46.0%, p<0.001), and more patients showed high adherence (PDC > 0.8) with bimatoprost than with travoprost (29.1% vs 22.3%, p<0.001). Similar proportions of patients had low adherence (PDC ≤0.2) with bimatoprost 0.01% and travoprost with sofZia (20.7% vs 22.2%; p>0.05). Significantly more patients remained on continuous treatment with bimatoprost than with travoprost over the 12-month follow-up period (29.5% [95% CI 28.3-30.8%] vs 24.2% [95% CI 23.2-25.2%], p<0.001). Sensitivity analyses performed in subcohorts of elderly (≥65 years) patients and ocular hypotensive treatment-naïve patients produced qualitatively similar findings.

Conclusions: In clinical practice, patients demonstrated superior adherence and persistence with bimatoprost 0.01% than with travoprost 0.004% with sofZia ophthalmic solution.

Keywords: 460 clinical (human) or epidemiologic studies: health care delivery/economics/manpower  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×